Nuclear Medicine

Astatine-211 Breakthrough Offers Targeted Cancer Treatment Alternative

Astatine-211 Breakthrough Offers Targeted Cancer Treatment Alternative

Texas A&M University researchers have developed a cancer treatment using astatine-211 that targets malignant cells while sparing healthy tissue, representing a significant advancement in precision radiotherapy.

November 13, 2025
LabConnect and The Bracken Group Forge Strategic Partnership to Enhance Radiopharmaceutical Trial Support

LabConnect and The Bracken Group Forge Strategic Partnership to Enhance Radiopharmaceutical Trial Support

LabConnect's collaboration with The Bracken Group addresses the growing demand for specialized radiopharmaceutical expertise in clinical trials, positioning the partnership to better serve biotech and pharmaceutical companies developing targeted treatments and diagnostics.

September 23, 2025